-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Why Teladoc (TDOC) Stock is Poised to Capture the Future of Healthcare
TDOC stock has popped more than 50% from its lows late last year. It is still under my recommended buy price… but I don’t expect it to stay that way for long.
New Cannabis Research Will Be Bittersweet for Tilray Stock
Important news from the U.S. Drug Enforcement Administration will be bittersweet for Tilray stock and its cannabis peers.
Why the Future of Canopy Growth Stock Is in the Hands of the President
President Trump recently made positive comments about federally legalized cannabis. That’s good news for Canopy Growth and CGC stock.
New Deals in Europe Could Boost Tilray Stock
After missing analyst estimates on profit loss, a new shipping agreement could be just what Tilray stock needs to soar high again.
Strong Fundamentals Make Cronos Stock a Value Play
CRON stock could continue to show strong revenue growth, making this dip a great buying opportunity in Cronos.
Aurora Cannabis Needs to Keep its Finger on the Marijuana Pulse
Aurora Cannabis has a viable story, but it could cement its long-term growth by entering the U.S. marijuana market.
CGC Stock Very Well May Be Trading Sideways for Awhile
Despite some positive developments Canopy Growth Corporation continues to disappoint shareholders as CGC stock trends lower.
Cronos Group’s Deal with Altria Presents ESG Concerns for CRON Stock
Cronos Group stock may not be attractive to institutions with ESG concerns. That is because its deal with Altria makes it a sin stock.
Can Aurora Cannabis Sales Overcome the Black Market?
Are the sales of Aurora Cannabis and other cannabis growers being affected by the black market? I think so ... here's why.
Is Aurora Cannabis Stock the Top Pot Play?
With ACB stock nearing 2019 lows and Q4 earnings due in two weeks, is now the time to add Aurora Cannabis to your portfolio?
Marijuana Stocks: One Chart Says Now Is The Time to Buy
Don’t get caught in the herd of doubters running for the hills. The long-term story for marijuana stocks is intact, and today is the day to buy.
Hexo Stock Smokes its Competition
In an emerging industry like cannabis, when one stock drops, they all drop. But a look at Hexo shows not all cannabis companies are the same.
Hexo Stock Drops as the Company Continues to Lose Money
HEXO stock has dropped by 50% in just four months. Investors are now coming to terms with the fact that the company is losing money.
Digital Healthcare Stocks: The IPO Market in This Under-the-Radar Industry Is Heating Up
Not every industry has joined the IPO party. Digital healthcare stocks have been left out completely. But, that's about to change.
Should Investors Buy Aurora Cannabis Stock At Current Levels?
The cannabis industry's fundamentals do not fully support ACB's stock's high valuation.
What Investors Should Know From Cronos Stock’s Earnings Release
CRON stock just released its second-quarter earnings and the price of CRON stock has trended lower since then.
Canopy Growth Stock Is Short on Fundamentals, But High on Potential
The markets have punished Canopy Growth stock for pinging red flags on fundamental metrics like goodwill. However, this emphasis misses the point that CGC currently runs not on fundamentals but on narratives.
